MannKind Corporation

Management

show all
Michael Castagna
Chief Executive Officer
Michael Castagna

Michael Castagna is our Chief Executive Officer and serves on the Board of Directors for MannKind Corporation. Dr. Castagna has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries. He joins MannKind from Amgen, Inc., where he spent over three years as Vice President, Global Commercial Lead for a portfolio of nine biosimilar drugs, and Vice President, Global Lifecycle Management. Prior to Amgen, Dr. Castagna, was Executive Director of Bristol-Myers Squibb’s Immunology franchise, where he served as co-lead to relaunch Orencia IV and launch Orencia SC, both rheumatoid arthritis drugs. Before BMS, Dr. Castagna was with Sandoz (Novartis) as Vice President and Division Head for Biopharmaceuticals, North America, where he established the US Biologics Business Unit and relaunched its lead product, Omnitrope, a human growth hormone. Prior to Sandoz, Dr. Castagna held a variety of positions with EMD (Merck), Serono, Pharmasset and DuPont Pharmaceuticals. Dr. Castagna serves on the board of directors of Pet Partners headquartered in Bellevue, Washington.

Dr. Castagna received his Bachelors of Science – Pharmacy degree from Philadelphia College of Pharmacy, his Doctor of Pharmacy from Massachusetts College of Pharmacy, and his MBA from the Wharton School of Business at the University of Pennsylvania.


Holdings: 212,500 shares     View Transactions
Date Type Shares Traded Price Range
08/26/16 Buy 17,500 0.78
08/24/16 Buy 15,000 0.87
08/23/16 Buy 25,000 0.94
08/12/16 Buy 25,000 1.00
05/19/16 Acquisition (Non Open Market) 80,000 n/a
05/17/16 Buy 50,000 0.93
Steven Binder
Chief Financial Officer
Steven Binder

Steven Binder is our Chief Financial Officer for MannKind Corporation.  Mr. Binder has over 25 years of experience in the healthcare industry. He most recently spent four years at Stryker Corporation, a leading global medical technology company, where he served as Vice President and Chief Financial Officer for Stryker’s International Group, based in Singapore. Prior to Stryker, Mr. Binder served in a series of senior leadership roles at Bristol-Myers Squibb Company, an innovative global biopharmaceutical company. His last four positions at BMS were Vice President, Finance roles over different geographic operating units: United States (2012-2013), Europe (2008-2011), AsiaPacific (2005-2007), and Japan (2003-2005). Prior to his international experience, Mr. Binder served in three senior leadership roles for Oncology Therapeutics Network, a U.S. based independent subsidiary of BMS: Vice President, Strategic Development (2001-2003), Vice President, Customer Operations (2000-2001), and Chief Financial Officer (1997-2000). Before OTN, Mr. Binder progressed through three finance and accounting roles for BMS Worldwide Medicines Group after joining the company in 1992. Before BMS, he worked for Deloitte & Touche in a series of auditing roles with increasing responsibility over an eight year period beginning in 1984. Mr. Binder received a B.S. degree in Accounting and Business Administration from Muhlenberg College and is a Certified Public Accountant.


Joseph Kocinsky
Chief Technology Officer
Joseph Kocinsky

Joseph Kocinsky is our Corporate Vice President of Technical Operations and Chief Technology Officer. Mr. Kocinsky has over 28 years experience in the pharmaceutical industry in technical operations and product development. Prior to joining MannKind in 2003, he held a variety of technical and management positions with increased responsibility at Schering-Plough.

Mr. Kocinsky holds a bachelor’s degree in Chemical Engineering and a master’s degree in Biomedical Engineering from New Jersey Institute of Technology and a master’s degree in Business Administration from Seton Hall University.


Holdings: 23,010 shares     View Transactions
Date Type Shares Traded Price Range
08/28/17 Disposition (Non Open Market) 353 1.55
08/22/17 Disposition (Non Open Market) 229 1.41
08/21/17 Disposition (Non Open Market) 212 1.46
08/27/16 Disposition (Non Open Market) 1,763 0.79
08/22/16 Disposition (Non Open Market) 846 0.98
08/21/16 Disposition (Non Open Market) 912 0.98
08/16/16 Disposition (Non Open Market) 1,645 1.00
10/14/15 Statement of Ownership 0 n/a
Patrick McCauley
Chief Commercial Officer
Patrick McCauley

Patrick McCauley is our Chief Commercial Officer for MannKind Corporation.  Mr. McCauley has over 25 years of experience in the biopharmaceutical industry. He has spent the last twelve years at Astellas Pharma in a series of senior sales and compliance leadership roles of increasing responsibility. Prior to Astellas, Mr. McCauley was a member of the U.S. commercialization team and held a sales leadership role with Yamanouchi Pharma before the merger of Yamanouchi and Fujisawa Pharma to create Astellas in 2005. Before Astellas/Yamanouchi, Mr. McCauley spent thirteen years with DuPont Pharmaceuticals and one year with Bristol-Myers Squibb which acquired DuPont Pharmaceuticals in 2001. At DuPont and Bristol-Myers Squibb, Mr. McCauley held a series of leadership roles across the sales, contracting and pricing, and clinical areas. Throughout his various career moves, Mr. McCauley has developed deep commercial expertise serving both specialty and primary care healthcare providers. He received a MBA degree from the Kellogg School of Management at Northwestern University, a JD from the South Texas College of Law, and a BA in Economics from the University of Notre Dame.


David B. Thomson
Corporate Vice President, General Counsel and Corporate Secretary
David B. Thomson

David B. Thomson, Ph.D., J.D. has been our Corporate Vice President, General Counsel and Corporate Secretary since January 2002. Prior to joining us, he practiced corporate/commercial and securities law at the Toronto law firm of Davies Ward Phillips & Vineberg LLP. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University in New York. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.


Holdings: 34,067 shares     View Transactions
Date Type Shares Traded Price Range
08/28/17 Disposition (Non Open Market) 303 1.55
08/22/17 Disposition (Non Open Market) 170 1.41
08/21/17 Disposition (Non Open Market) 183 1.46
08/27/16 Disposition (Non Open Market) 1,513 0.79
08/22/16 Disposition (Non Open Market) 846 0.98
08/21/16 Disposition (Non Open Market) 912 0.98
08/16/16 Disposition (Non Open Market) 1,645 1.00
08/27/15 Acquisition (Non Open Market) 16,100 n/a
08/22/15 Disposition (Non Open Market) 1,175 3.79
08/21/15 Disposition (Non Open Market) 1,266 3.79
08/18/15 Disposition (Non Open Market) 2,153 4.15
08/16/15 Disposition (Non Open Market) 2,283 4.09
02/23/15 Acquisition (Non Open Market) 45,000 n/a
02/23/15 Disposition (Non Open Market) 16,911 6.43
02/19/15 Automatic Sell 68,662 7.19
02/05/15 Automatic Sell 80,000 7.00
02/05/15 Option Execute 80,000 1.69
11/24/14 Automatic Sell 118,114 6.14
08/22/14 Disposition (Non Open Market) 1,175 7.09
08/21/14 Acquisition (Non Open Market) 9,700 n/a
08/19/14 Disposition (Non Open Market) 1,696 7.23
08/18/14 Disposition (Non Open Market) 2,153 6.86
08/16/14 Disposition (Non Open Market) 2,283 6.86
08/11/14 Acquisition (Non Open Market) 220,000 n/a
08/11/14 Disposition (Non Open Market) 114,796 8.53
08/07/14 Automatic Sell 30,000 8.16
08/07/14 Option Execute 30,000 1.69
07/17/14 Automatic Sell 30,000 9.42
07/17/14 Option Execute 30,000 1.69
06/27/14 Acquisition (Non Open Market) 247,000 n/a
06/27/14 Disposition (Non Open Market) 128,886 10.00
06/26/14 Automatic Sell 30,000 10.51
06/26/14 Option Execute 30,000 1.69
06/04/14 Automatic Sell 133,000 9.95
06/04/14 Option Execute 133,000 6.85 - 7.48
05/19/14 Automatic Sell 15,091 7.50
12/11/13 Automatic Sell 150,000 5.00
12/11/13 Option Execute 150,000 1.69
11/21/13 Acquisition (Non Open Market) 110,000 n/a
11/21/13 Disposition (Non Open Market) 41,338 4.88
08/28/13 Automatic Sell 10,000 5.80
08/26/13 Sell 9,204 5.75
08/22/13 Acquisition (Non Open Market) 9,000 n/a
08/19/13 Disposition (Non Open Market) 2,350 5.77
08/18/13 Disposition (Non Open Market) 1,551 5.77
08/16/13 Disposition (Non Open Market) 1,645 6.64
03/03/13 Disposition (Non Open Market) 3,401 2.62
08/19/12 Disposition (Non Open Market) 2,294 2.35
08/18/12 Disposition (Non Open Market) 1,514 2.35
08/16/12 Acquisition (Non Open Market) 17,500 n/a
Dr. Stuart A. Tross
Chief People Officer
Stuart Tross

Stuart A. Tross, Ph.D. is our Chief People Officer, with responsibilities for Human Resources, Information Technology, and West Coast Facilities. Dr. Tross joins MannKind with extensive experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organization Psychology from the Georgia Institute of Technology. 


Holdings: 100,000 shares     View Transactions
Date Type Shares Traded Price Range
02/16/17 Acquisition (Non Open Market) 100,000 n/a
Raymond W. Urbanski, MD, PhD
Chief Medical Officer
Raymond W. Urbanski, MD, PhD

Raymond W. Urbanski, MD, PhD is our Chief Medical Officer. Dr. Urbanski has more than 25 years of research, clinical, and pharmaceutical industry experience developing numerous new drugs and indications across oncology, rheumatology, cardiology, endocrinology, and immunology. Prior to joining MannKind, he most recently held the position of Chief Medical Officer at Mylan, Inc. From 2004 to 2011 Dr. Urbanski was with Pfizer, advancing to the positon of Vice President and Medical Head of the Established Products Business Unit. He also served as Vice President of R&D and CMO at Suntory Pharmaceuticals. Dr. Urbanski earned both his MD and Ph.D. in Pharmacology and Toxicology, at the University of Medicine and Dentistry of New Jersey – New Jersey Medical School. He completed his residency and fellowship training at Thomas Jefferson University Hospital in Philadelphia.


Holdings: 2,924 shares     View Transactions
Date Type Shares Traded Price Range
08/10/17 Sell 296 1.15
10/14/15 Statement of Ownership 0 n/a
Rose Alinaya
SVP
Rose Alinaya

Rose Alinaya is our Senior Vice President for MannKind Corporation.

Ms. Alinaya has been our Vice President, Finance since March 2011 after serving as our Corporate Controller since June 2003 with responsibility for finance, accounting, tax, treasury, investor relations and risk management.

Ms. Alinaya began her career at Deloitte & Touche LLP, graduating from California State University, Northridge. She is also a member of the American Institute of Certified Public Accountants and a member of the California Society of Certified Public Accountants.

 


Holdings: 29,543 shares     View Transactions
Date Type Shares Traded Price Range
08/28/17 Disposition (Non Open Market) 243 1.55
08/22/17 Disposition (Non Open Market) 160 1.41
08/21/17 Disposition (Non Open Market) 145 1.46
06/30/17 Buy 2,000 1.23
01/03/17 Buy 9,043 0.54
07/06/16 Acquisition (Non Open Market) 6,294 1.00
07/06/16 Sell 6,294 1.06
02/28/16 Statement of Ownership 0 n/a
02/18/16 Acquisition (Non Open Market) 49,000 n/a
Courtney Barton
Vice President, Chief Compliance Officer
Courtney Barton

Ms. Barton joined MannKind Corporation in March 2017 and is responsible for leading all aspects of our corporate and healthcare compliance programs. Ms. Barton brings broad, global compliance and ethics expertise to the role, having begun her compliance and ethics career at Winn-Dixie Stores, Incorporated before transitioning to roles in the pharmaceutical and medical device sector with Bausch + Lomb, Allergan, KYTHERA (Allergan) and Anacor (Pfizer). She has also held positions with Merrill Lynch and Janus, including an international appointment. A graduate of Syracuse University, Ms. Barton holds Bachelor’s degrees in Political Science and International Relations and is a Certified Compliance and Ethics Professional (CCEP) and Certified Information Privacy Professional (CIPP US/E).


Stock transaction information provided by EDGAR Online. MannKind Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.